Researchers recently published long-term data demonstrating the sustained success of Hemophilia B gene therapy using fidanacogene elaparvovec. This single-dose treatment aims to provide lasting Factor IX (FIX) expression by delivering the high-activity FIX-R338L variant. Initially, participants with severe or moderately severe deficiency received a single infusion. Following the first year, they transitioned into a five-year long-term follow-up study. The results confirm that this therapy offers a durable alternative to lifelong prophylaxis.

Long-Term Efficacy of Hemophilia B Gene Therapy

The primary measure of success remained the durability of FIX activity. Notably, the mean FIX activity was 24.7% at Year 2 and reached 26.1% by Year 6. Consequently, all 14 participants remained off FIX prophylaxis for the entire duration. Furthermore, the median annualized bleeding rate (ABR) was 0.0 throughout each year of follow-up. About 71% of participants experienced no treated bleeding events at all. These findings suggest that a single infusion can effectively convert a severe phenotype into a mild one for at least six years.

Safety and Patient-Reported Success

Safety remains a critical concern for any viral vector-based treatment. During the follow-up period, investigators reported no treatment-related serious adverse events. While some participants showed increased liver enzymes early on, none required corticosteroid intervention. Moreover, the study reported no liver masses, malignancies, or thrombotic events. Participants also noted significant improvements in joint health and quality of life. Specifically, patient-reported outcomes showed stable or improved target joint scores throughout the six-year period.

In conclusion, fidanacogene elaparvovec represents a transformative shift in managing congenital factor IX deficiency. It provides a favorable safety profile alongside sustained clinical benefits. As India advances its own gene therapy infrastructure, these long-term global results provide a vital roadmap for local clinical adoption.

Frequently Asked Questions

How long does the effect of Hemophilia B gene therapy last?

Clinical data shows that FIX activity remains stable for at least six years following a single infusion of fidanacogene elaparvovec, with many patients maintaining levels in the mild hemophilia range.

Is prophylaxis still necessary after gene therapy?

In this long-term study, none of the participants needed to resume factor IX prophylaxis, as the therapy provided sufficient endogenous FIX production to prevent spontaneous bleeds.

What are the common side effects observed in the long term?

Commonly reported effects include transient elevations in liver enzymes (ALT/AST). However, no serious treatment-related adverse events or malignancies were observed during the six-year follow-up.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Samelson-Jones BJ et al. Safety, efficacy and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B. Blood Adv. 2026 Feb 24. doi: undefined. PMID: 41734390.

U.S. Food and Drug Administration. FDA approves first gene therapy for adults with hemophilia B. April 2024.

ClinicalTrials.gov. Long-term follow-up of fidanacogene elaparvovec in hemophilia B. Identifier: NCT03307980.